S'abonner

An investigation of clinical characteristics and antimicrobial agent susceptibility patterns in clinical Comamonas testosteroni isolates: An increasingly prevalent nosocomial pathogen - 05/03/23

Doi : 10.1016/j.idnow.2022.09.017 
Bahadır Orkun Ozbay a, , 1 , Adalet Aypak a, Aliye Bastug b, Ömer Aydos a, İpek Mumcuoglu c, Sevim Gayenur Büyükberber c, Ayşe Müge Karcıoğlu d, Hurrem Bodur b
a Ministry of Health, Ankara City Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey 
b Health Science University Turkey, Ankara City Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey 
c Ministry of Health, Ankara City Hospital, Department of Medical Microbiology, Ankara, Turkey 
d Ministry of Health, Ankara City Hospital, Department of Critical Care Medicine, Turkey 

Corresponding author at: Ankara City Hospital, Department of Infectious Disease and Clinical Microbiology University, 1604, Street, No: 9, 06800 Çankaya/Ankara, Turkey.Ankara City HospitalDepartment of Infectious Disease and Clinical MicrobiologyUniversity1604, Street, No: 906800 Çankaya/AnkaraTurkey

Highlights

Comamonas testosteroni is a gram-negative bacillus, known before 1987as Pseudomonas testosteroni.
Although known as a rare pathogen, its frequency has been increasing. Data regarding its antibiotic susceptibility are insufficient.
To date, forty-four cases have been reported in the literature.
Even though resistance to carbapenems is increasing, third-generation cephalosporins are still seen as suitable options in treatment.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

Comamonas testosteroni is a gram-negative bacillus, known before 1987 as Pseudomonas testosteroni. Although considered as a rare pathogen, its frequency has been increasing. Data regarding its antibiotic susceptibility are insufficient. To date, forty-four cases have been reported in the literature. In this study, we identified the C. testosteroni infections observed in our hospital and evaluated their antimicrobial agent susceptibility patterns compared with cases reported in the literature.

Methods

For the purposes of the present study, patients admitted to hospital between November 2019 and December 2020 were screened. Those with clinical and laboratory signs of infection with positive C. testosteroni growth in culture were enrolled. Clinical isolates obtained from the samples processed in accordance with standard microbiological examination procedures in our laboratory were defined by MALDI-TOF mass spectrometry with 99.9% probability as C. testosteroni.

Results

C testosteroni infection was detected between November 2019 and December 2020 in eight patients in our hospital. Six of them had a bloodstream infection (BSI), one had pneumonia, and one had urinary tract infection due to C. testosteroni. Coexistence of COVID-19 was detected in four patients. Six out of the eight cases with BSI had hospital-acquired infection and all of the infections were healthcare-associated. When antimicrobial agent susceptibility results reported in the literature were evaluated in combination with the current results, ceftazidime and meropenem were found to be the most susceptible agents (96.1% and 80%, respectively).

Conclusions

The frequency of nosocomial C. testosteroni infections and resistance to antimicrobial agents are gradually increasing. While resistance to carbapenems is on the upswing, third-generation cephalosporins are still seen as suitable treatment options.

Le texte complet de cet article est disponible en PDF.

Keywords : Comamonas infection, Comamonas testosteroni, Antimicrobial susceptibility


Plan


© 2022  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 53 - N° 2

Article 104622- mars 2023 Retour au numéro
Article précédent Article précédent
  • Factors associated with daptomycin consumption in French hospitals between 2019 and 2020: A nationwide surveillance study
  • A. Loffler, A.-G. Venier, A. Jouzeau, M. Péfau, L. Dugravot, A. Chabaud, L. Simon, C. Dumartin
| Article suivant Article suivant
  • Molecular detection of Aspergillus in respiratory samples collected from patients at higher risk of chronic pulmonary aspergillosis
  • M. Oliveira, M. Pinto, H. Simões, J.P. Gomes, C. Veríssimo, R. Sabino

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.